English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The combination of dopamine with anticancer drugs can result in enhanced anticancer activity. Polymer-drug conjugates (PDCs) containing anticancer drugs, such as platinum-based drugs, and doxorubicin together with dopamine were prepared. PDCs were characterized followed by  in vitro  cytotoxicity studies using pheochromocytoma (PC12) cell lines. The particle size analysis revealed the particles sizes of the PDCs in the range of 15.68–179.8 nm with PDI in the range of 0.373–0.687. T3 and T6 displayed promising cytotoxic effects with IC 50  values of 5.25 and 11.56 μg/mL when compared to the free drugs (29.65 μg/mL for K 2 PtCl 4  and 14.96 μg/mL for procaine). The findings revealed that combining dopamine with anticancer drugs is a promising approach to develop effective therapeutics for the treatment of cancer.

Dopamine-Loaded Polymer-Drug Conjugates for Potential Synergistic Anti-Cancer Treatment